Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The investigator believes simeprevir concentrations are unchanged when administered in
combination with dolutegravir relative to administration alone. The investigator believes
dolutegravir concentrations are unchanged when administered in combination with simeprevir.
Additionally, the investigator believes simeprevir and dolutegravir are safe when
administered alone and in combination.